Ascletis to present positive ASC30 data at major diabetes meeting

Ascletis Pharma Inc. announced it will present 28-day multiple ascending dose study results for its oral small molecule GLP-1R agonist, ASC30, at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting in Vienna, Austria. The presentation, titled "ASC30, an oral GLP-1R biased small molecule agonist demonstrated superior weight loss in participants with obesity: a 28-day multiple ascending dose study," will occur on September 16, 2025.

ASC30, an investigational new chemical entity protected by U.S. and global compound patents until 2044, is designed for both oral tablet and subcutaneous injection administrations. Ascletis chairman and CEO, Jinzi Jason Wu, expressed optimism that these efficacy and safety data will position ASC30 oral tablets as a potentially differentiated option for obesity treatment.

The company also anticipates reporting topline data from its Phase IIa clinical study of ASC30 oral tablets in participants with obesity or overweight in the fourth quarter of 2025.